Potent immunogenicity and broad-spectrum protection potential of microneedle array patch-based COVID-19 DNA vaccine candidates encoding dimeric RBD chimera of SARS-CoV and SARS-CoV-2 variants

References

• WHO. Interim statement on COVID-19 vaccines in the context of the circulation of the Omicron SARS-CoV-2 variant from the WHO Technical Advisory Group on COVID-19 vaccine composition (TAG-CO-VAC). 2022. Available from: https://www.who.int/news/item/11-01-2022-interim-statement-on-covid-2019-vaccines-in-the-context-of-the-circulation-of-the-omicron-sars-cov-2022-variant-from-the-who-technical-advisory-group-on-covid-2019-vaccine-composition.
   Google Scholar
• Xu K, Fan C, Han Y, et al. Immunogenicity, efficacy and safety of COVID-19 vaccines: an update of data published by 31 December 2021. Int Immunol. 2022;34(12). DOI:10.1093/intimm/dxac031
   Web of Science ®Google Scholar
• Abu-Raddad LJ, Chemaitelly H, Butt AA. Effectiveness of the BNT162b2 COVID-19 vaccine against the B.1.1.7 and B.1.351 variants. N Engl J Med. 2021;385(2):187–189.
   PubMed Web of Science ®Google Scholar
• Krause PR, Fleming TR, Longini IM, et al. SARS-CoV-2 variants and vaccines. N Engl J Med. 2021;385(2):179–186.
   PubMed Web of Science ®Google Scholar
• Cao Y, Wang J, Jian F, et al. Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies. Nature. 2022;602(7898):657–663.
   PubMed Web of Science ®Google Scholar
• Cele S, Jackson L, Khoury DS, et al. Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization. Nature. 2022;602(7898):654–656.
   PubMed Web of Science ®Google Scholar
• Dejnirattisai W, Huo J, Zhou D, et al. SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses. Cell. 2022;185(3):467–484.e15.
   PubMed Web of Science ®Google Scholar
• Karim SSA, Karim QA. Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic. Lancet. 2021;398(10320):2126–2128.
   PubMedGoogle Scholar
• Garcia-Beltran WF, Lam EC, St. Denis K, et al. Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity. Cell. 2021;184(9):2372–2383.e9.
   PubMed Web of Science ®Google Scholar
• Hoffmann M, Kruger N, Schulz S, et al. The Omicron variant is highly resistant against antibody-mediated neutralization: implications for control of the COVID-19 pandemic. Cell. 2022;185(3):447–456.e11.
   PubMed Web of Science ®Google Scholar
• Qu P, Evans JP, Faraone J, et al. Distinct neutralizing antibody escape of SARS-CoV-2 omicron subvariants BQ.1, BQ.1.1, BA.4.6, BF.7 and BA.2.75.2. bioRxiv [Preprint]. 2022:2022.10.19.512891.
   Google Scholar
• Li Q, Wu J, Nie J, et al. The impact of mutations in SARS-CoV-2 spike on viral infectivity and antigenicity. Cell. 2020;182(5):1284–1294.e9.
   PubMed Web of Science ®Google Scholar
• Wang Q, Zhang Y, Wu L, et al. Structural and functional basis of SARS-CoV-2 entry by using human ACE2. Cell. 2020;181(4):894–904.e9.
   PubMed Web of Science ®Google Scholar
• Khoury DS, Cromer D, Reynaldi A, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med 2021;27:1205–1211.
   PubMed Web of Science ®Google Scholar
• Shi R, Shan C, Duan X, et al. A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2. Nature. 2020;584:120–124.
   PubMed Web of Science ®Google Scholar
• An Y, Li S, Jin X, et al. A tandem-repeat dimeric RBD protein-based COVID-19 vaccine ZF2001 protects mice and nonhuman primates. Emerg Microbes Infect. 2022;11:1058–1071.
   PubMed Web of Science ®Google Scholar
• Xu K, Gao P, Liu S, et al. Protective prototype-Beta and Delta-Omicron chimeric RBD-dimer vaccines against SARS-CoV-2. Cell. 2022;185(13):2265–2278.e14.
   PubMed Web of Science ®Google Scholar
• Tan C-W, Chia W-N, Young BE, et al. Pan-sarbecovirus neutralizing antibodies in BNT162b2-immunized SARS-CoV-1 survivors. N Engl J Med. 2021;385(15):1401–1406.
   PubMed Web of Science ®Google Scholar
• Liu MA. DNA vaccines: an historical perspective and view to the future. Immunol Rev. 2011;239:62–84.
   PubMed Web of Science ®Google Scholar
• Gurunathan S, Klinman DM, Seder RA. DNA vaccines: immunology, application, and optimization. Annu Rev Immunol. 2000;18:927–974.
   PubMed Web of Science ®Google Scholar
• Conforti A, Marra E, Palombo F, et al. COVID-eVax, an electroporated DNA vaccine candidate encoding the SARS-CoV-2 RBD, elicits protective responses in animal models. Mol Ther. 2022;30:311–326.
   PubMed Web of Science ®Google Scholar
• Smith TRF, Patel A, Ramos S, et al. Immunogenicity of a DNA vaccine candidate for COVID-19. Nat Commun. 2020;11(1):2601.
   PubMed Web of Science ®Google Scholar
• Mallapaty S. India's DNA COVID vaccine is a world first – more are coming. Nature. 2021;597:161–162.
   PubMed Web of Science ®Google Scholar
• Lee KJ, Jeong SK, Roh DH, et al. A practical guide to the development of microneedle systems – in clinical trials or on the market. Int J Pharm. 2020;573:118778.
   PubMed Web of Science ®Google Scholar
• Menon I, Bagwe P, Gomes KB, et al. Microneedles: a new generation vaccine delivery system. Micromachines (Basel). 2021;12(4):435.
   PubMed Web of Science ®Google Scholar
• Nagao K, Ginhoux F, Leitner WW, et al. Murine epidermal Langerhans cells and langerin-expressing dermal dendritic cells are unrelated and exhibit distinct functions. Proc Natl Acad Sci USA. 2009;106:3312–3317.
   PubMed Web of Science ®Google Scholar
• Seneschal J, Clark RA, Gehad A, et al. Human epidermal Langerhans cells maintain immune homeostasis in skin by activating skin resident regulatory T cells. Immunity. 2012;36:873–884.
   PubMed Web of Science ®Google Scholar
• Kabashima K, Honda T, Ginhoux F, et al. The immunological anatomy of the skin. Nat Rev Immunol. 2019;19:19–30.
   PubMed Web of Science ®Google Scholar
• Zhang SJ, Zhao SS, Jin X, et al. Microneedles improve the immunogenicity of DNA vaccines. Hum Gene Ther. 2018;29(9):1004–1010.
   PubMed Web of Science ®Google Scholar
• Cole G, Ali AA, McErlean E, et al. DNA vaccination via RALA nanoparticles in a microneedle delivery system induces a potent immune response against the endogenous prostate cancer stem cell antigen. Acta Biomater. 2019;96:480–490.
   PubMed Web of Science ®Google Scholar
• Yin Y, Su W, Zhang J, et al. Separable microneedle patch to protect and deliver DNA nanovaccines against COVID-19. ACS Nano. 2021;15:14347–14359.
   PubMed Web of Science ®Google Scholar
• Zhao G, Zhang Z, Ding Y, et al. A DNA vaccine encoding the full-length spike protein of beta variant (B.1.351) elicited broader cross-reactive immune responses against other SARS-CoV-2 variants. Vaccines (Basel). 2023;11:513. https://doi.org/10.3390/vaccines11030513.
   PubMed Web of Science ®Google Scholar
• Li Z-x, Feng S, Zhang H, et al. Immunogenicity and protective efficacy of a DNA vaccine inducing optimal expression of the SARS-CoV-2 S gene in hACE2 mice. Arch Virol. 2022;167(12):2519–2528.
   PubMedGoogle Scholar
• Moss P. The T cell immune response against SARS-CoV-2. Nat Immunol. 2022;23:186–193.
   PubMed Web of Science ®Google Scholar
• Dakal TC. Antigenic sites in SARS-CoV-2 spike RBD show molecular similarity with pathogenic antigenic determinants and harbors peptides for vaccine development. Immunobiology. 2021;226:152091.
   PubMed Web of Science ®Google Scholar
• Kong L, Lee DE, Kadam RU, et al. Structural flexibility at a major conserved antibody target on hepatitis C virus E2 antigen. Proc Natl Acad Sci USA. 2016;113(45):12768–12773.
   PubMed Web of Science ®Google Scholar
• de Taeye SW, de la Peña AT, Vecchione A, et al. Stabilization of the gp120 V3 loop through hydrophobic interactions reduces the immunodominant V3-directed non-neutralizing response to HIV-1 envelope trimers. J Biol Chem. 2018;293(5):1688–1701.
   PubMed Web of Science ®Google Scholar
• Qu P, Evans JP, Faraone J, et al. Distinct neutralizing antibody escape of SARS-CoV-2 Omicron subvariants BQ.1, BQ.1.1, BA.4.6, BF.7 and BA.2.75.2. bioRxiv preprint. https://doi.org/10.1101/2022.10.19.512891.
   Google Scholar
• Ding Y, Fan F, Zhang X, et al. A COVID-19 DNA vaccine candidate encoding tandem RBD Chimera of SARS-CoV-1 and SARS-CoV-2 Omicron BA.5 elicits broadly neutralizing antibodies against multiple SARS-CoV-2 variants including the currently circulating Omicron BA.4/5, BF.7 and BQ1.1. submitted manuscript.
   Google Scholar
• Hirobea S, Susaia R, Takeuchia H, et al. Characteristics of immune induction by transcutaneous vaccination using dissolving microneedle patches in mice. Internat J Pharmac. 2021;601:120563.
   PubMed Web of Science ®Google Scholar